{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:10Z","timestamp":1787161270806,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunosuppression is a recognized risk factor for severe and disseminated coccidioidomycosis; however, data describing outcomes in patients with inflammatory bowel disease (IBD) receiving advanced therapy, including biologics and small molecules, remain limited. We aim to describe the prevalence, clinical presentation, treatment patterns, and outcomes of coccidioidomycosis in IBD patients receiving advanced therapy at an endemic tertiary care center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective observational study of adult patients with IBD at Mayo Clinic Arizona diagnosed with coccidioidomycosis between 2023 and 2026. Patients were included if IBD diagnosis preceded coccidioidomycosis diagnosis and advanced therapy had been active for at least 4\u2009weeks before infection. Cases were classified as proven, probable, or possible based on microbiologic, clinical, radiographic, and serologic criteria. Clinical outcomes included antifungal treatment duration, hospitalization related to coccidioidomycosis or IBD, IBD treatment modification after diagnosis, re-emergence of coccidioidomycosis symptoms, and IBD-related surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 48 patients met inclusion criteria. Among 1083 tested IBD patients receiving advanced therapy, coccidioidomycosis positivity prevalence was 4.4% when including all serologically positive patients and 1.9% when restricted to proven or probable cases. The median age at coccidioidomycosis diagnosis was 40\u2009years (range 19-87 years), and 30 (62.5%) of 48 had Crohn\u2019s disease. Proven or probable infection was identified in 21 (43.8%) of 48 patients, while 14 (29.2%) of 48 patients were classified as possible. Antifungal therapy was prescribed in 32 (66.7%) of 48 patients, including all proven cases, 15 (88.2%) of 17 probable cases, 9 (64.3%) of 14 possible cases, and 3 (25.0%) of 12 nondiagnostic cases. Among proven\/probable\/possible cases, the median antifungal treatment duration was 174\u2009days (range 8-831 days). Advanced IBD therapy was continued in 3 (75.0%) of 4 proven cases, 9 (52.9%) of 17 probable cases, 12 (85.7%) of 14 possible cases, and all nondiagnostic cases. Hospitalization occurred in 6 (12.5%) of 48 of the cohort, all of which were proven\/probable cases. Most patients remained on advanced therapy after diagnosis, although tumor necrosis factor \u03b1 inhibitors were the most interrupted or discontinued agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this endemic tertiary care cohort, management decisions varied according to diagnostic certainty. Patients with proven or probable coccidioidomycosis were more likely to receive antifungal therapy and undergo advanced IBD therapy modification, whereas most patients with possible or nondiagnostic serologic findings remained on advanced therapy without major IBD-related complications. Prolonged antifungal treatment was common, highlighting the complexity of managing coccidioidomycosis in immunosuppressed patients with IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag168","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:13:39Z","timestamp":1786101219000},"source":"Crossref","is-referenced-by-count":0,"title":["Coccidioidomycosis in patients with inflammatory bowel disease receiving advanced therapy: An observational study from an endemic tertiary center"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6286-3855","authenticated-orcid":false,"given":"Fares","family":"Jamal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro J","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Viggiano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0350-6199","authenticated-orcid":false,"given":"Sandra","family":"Elmasry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Hamad","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina I","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin J","family":"Kaleta","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme P","family":"Ramos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan L","family":"Delafield","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis E","family":"Blair","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6440-6064","authenticated-orcid":false,"given":"Talha A","family":"Malik","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081913122094300_izag168-B1","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081913122094300_izag168-B2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.22037\/ghfbb.v18i2.3105","article-title":"Global prevalence and incidence of inflammatory bowel disease: a systematic review and meta-analysis of population-based studies","volume":"18","author":"Heydari","year":"2025","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"2026081913122094300_izag168-B3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"2026081913122094300_izag168-B4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3238\/arztebl.m2023.0142","article-title":"Treatment strategies in inflammatory bowel diseases","volume":"120","author":"Stallmach","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"2026081913122094300_izag168-B5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026081913122094300_izag168-B6","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026081913122094300_izag168-B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.15585\/mmwr.mm7506a3","article-title":"Regional increases in incidence of Coccidioidomycosis (Valley Fever) - Arizona, 2005-2022","volume":"75","author":"Kruger","year":"2026","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026081913122094300_izag168-B8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/cid\/ciy620","article-title":"The utility of screening for Coccidioidomycosis in recipients of inhibitors of tumor necrosis factor alpha","volume":"68","author":"Choi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026081913122094300_izag168-B9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1055\/s-0035-1562900","article-title":"Coccidioidomycosis: recent updates","volume":"36","author":"Twarog","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2026081913122094300_izag168-B10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/jim-2020-001655","article-title":"Coccidioidomycosis: a review","volume":"69","author":"Johnson","year":"2021","journal-title":"J Investig Med"},{"key":"2026081913122094300_izag168-B11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3201\/eid2302.160505","article-title":"Risk factors for disseminated coccidioidomycosis, United States","volume":"23","author":"Odio","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2026081913122094300_izag168-B12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s15010-017-1029-9","article-title":"Divergence in the approach to tumor necrosis factor alpha-inhibitor recipients with coccidioidomycosis","volume":"45","author":"Garrett","year":"2017","journal-title":"Infection"},{"key":"2026081913122094300_izag168-B13","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/acr.21784","article-title":"Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs","volume":"64","author":"Taroumian","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026081913122094300_izag168-B14","doi-asserted-by":"crossref","first-page":"S822","DOI":"10.14309\/01.ajg.0000953964.31097.7e","article-title":"S1081 Incidental diagnosis of coccidioidomycosis in inflammatory bowel disease is less likely associated with adverse clinic outcomes","volume":"118","author":"Alameri","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026081913122094300_izag168-B15","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1111\/myc.70040","article-title":"Fungal infections associated with TNF-inhibitors: a 20-year of a systematic review fungal infections and TNF-inhibitors","volume":"68","author":"Barbosa","year":"2025","journal-title":"Mycoses"},{"key":"2026081913122094300_izag168-B16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/art.39468","article-title":"Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors","volume":"68","author":"Salt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026081913122094300_izag168-B17","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1093\/mmy\/myy019","article-title":"Coccidioidomycosis in selected immunosuppressed hosts","volume":"57","author":"Blair","year":"2019","journal-title":"Med Mycol"},{"key":"2026081913122094300_izag168-B18","year":"2025"},{"key":"2026081913122094300_izag168-B19","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026081913122094300_izag168-B20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/mmy\/myaa109","article-title":"Coccidioidomycosis in patients with various inflammatory disorders treated with tumor necrosis factor alpha inhibitors","volume":"59","author":"Delafield","year":"2021","journal-title":"Med Mycol"},{"key":"2026081913122094300_izag168-B21","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1111\/jdv.19328","article-title":"Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - a population-based study","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081913122094300_izag168-B22","doi-asserted-by":"publisher","first-page":"e2557922","DOI":"10.1001\/jamanetworkopen.2025.57922","article-title":"Comparative safety of advanced therapies for Crohn disease","volume":"9","author":"Park","year":"2026","journal-title":"JAMA Netw Open"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag168\/70715208\/izag168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag168\/70715208\/izag168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:12:27Z","timestamp":1787159547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag168\/8766581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag168","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"izag168"}}